We are live on ! Find out more

996 hedge funds and large institutions have $35B invested in Biogen in 2023 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 341 increasing their positions, 363 reducing their positions, and 99 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more call options, than puts

Call options by funds: $748M | Put options by funds: $674M

11% more capital inflows, than outflows

Capital inflows: $2.8B | Capital outflows: $2.53B

0.33% more ownership

Funds ownership: 86.75% → 87.08% (+0.33%)

6% less repeat investments, than reductions

Existing positions increased: 341 | Existing positions reduced: 363

3% less funds holding

Funds holding: 1,030 → 996 (-34)

16% less first-time investments, than exits

New positions opened: 83 | Existing positions closed: 99

24% less funds holding in top 10

Funds holding in top 10: 25 → 19 (-6)

Holders
996
Holders Change
-34
Holders Change %
-3.3%
% of All Funds
15.84%
Holding in Top 10
19
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-24%
% of All Funds
0.3%
New
83
Increased
341
Reduced
363
Closed
99
Calls
$748​M
Puts
$674​M
Net Calls
+$73.9​M
Net Calls Change
+$290​M

BIIB Hedge Fund Activity: Q1 2023 in Review

996 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2023, worth a combined $35B — up 1.3% from $34.6B a quarter earlier.

Sellers outnumbered buyers: 99 funds closed out of BIIB and 83 opened new positions — a net loss of 16 holders — while 363 trimmed existing stakes and 341 added.

The largest buyer was JP Morgan Chase, adding an estimated $509M. The largest seller was Marshall Wace, cutting an estimated $197M.

  • 996 institutional investors held Biogen (BIIB) as of Q1 2023, down from 1,030 in Q4 2022.
  • Funds reported $35B of Biogen stock for Q1 2023, up 1.3% quarter-over-quarter.
  • 83 funds opened new Biogen positions in Q1 2023 and 99 closed out, a net change of -16 holders.
  • The largest Biogen buyer in Q1 2023 was JP Morgan Chase, an estimated $509M added.
  • The largest Biogen seller in Q1 2023 was Marshall Wace, an estimated $197M sold.

Based on aggregated 13F filings for Q1 2023.